UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 9, 2015
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
|
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes [ ]
|
No [X]
|
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 9 March 2015 – On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.
Under the programme initiated 30 January 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 30 January 2015 to 28 April 2015.
Since the announcement as of 2 March 2015, the following transactions have been made under the programme:
|
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
|
Accumulated, last announcement
|
4,349,481
|
|
1,273,628,489
|
|
2 March 2015
|
195,000
|
317.58
|
61,927,652
|
|
3 March 2015
|
210,000
|
316.45
|
66,455,214
|
|
4 March 2015
|
195,000
|
314.46
|
61,318,901
|
|
5 March 2015
|
180,000
|
317.58
|
57,164,292
|
|
6 March 2015
|
210,000
|
321.12
|
67,435,851
|
|
Accumulated under the programme
|
5,339,481
|
|
1,587,930,398
|
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 2,000 B shares in the period from 2 March 2015 to 6 March 2015. In addition, 134,251 Novo Nordisk B shares held by NNIT A/S are no longer considered part of Novo Nordisk treasury shares following the IPO of NNIT A/S which was completed on 6
Page 2 of 2
March 2015. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 63,978,333 B shares of DKK 0.20, corresponding to 2.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2015. As of 6 March 2015, Novo Nordisk has repurchased a total of 5,339,481 B shares equal to a transaction value of DKK 1,587,930,398.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
| Media: | ||
|
Anne Margrethe Hauge
|
+45 3079 3450
|
amhg@novonordisk.com
|
|
|
|
|
| Investors: | ||
|
Kasper Roseeuw Poulsen
|
+45 3079 4303
|
krop@novonordisk.com
|
|
Jannick Lindegaard Denholt
|
+45 3079 8519
|
jlis@novonordisk.com
|
|
Daniel Bohsen
|
+45 3079 6376
|
dabo@novonordisk.com
|
|
Melanie Raouzeos
|
+45 3075 3479
|
mrz@novonordisk.com
|
|
Frank Daniel Mersebach (US)
|
+1 609 235 8567
|
fdni@novonordisk.com
|
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
24 25 67 90
|
|
Company announcement No 17 / 2015
|
|||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
|
Date: March 9, 2015
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|